Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality.

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...

For patients with idiopathic intracranial hypertension, GLP-1 RA treatment is linked with improved clinical outcomes compared with conventional therapies.

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

GLP-1 agonists are medications that primarily treat type 2 diabetes and obesity. However, recent studies suggest they can lower blood pressure, reduce inflammation and improve lipid disorders.

GLP-1 receptor agonist medications have revolutionized weight management and diabetes treatment, offering significant benefits for millions of patients worldwide. However, these powerful ...

A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared to ...

The Extended Lifespan of GLP-1 Receptor Agonist Drugs from the Discovery of Pleiotropic Effects Glucagon-like peptide-1 (GLP-1) was first discovered in the 1980s as a regulator of glucose levels.

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Glucagon-like peptide-1 (GLP-1) receptor agonists used in patients with diabetes are associated with reduced risks of dozens of outcomes—as well as increased risks of others—when compared with other ...

The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3.0 years.